AstraZeneca has announced a partnership with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder. The collaboration involves the use of Quell's T-regulatory (Treg) cell engineering toolbox to develop autologous multi-modular Treg cell therapies, which will be manufactured through to the end of the first-in-human clinical study. AstraZeneca has initially provided $85 million for the project, but there is potential for development and commercialisation milestones and royalties down the line that could amount to more than $2 billion. The trend towards using successful cancer treatments in autoimmune disease is growing in popularity within both research and pharma circles.